Skip to content

Opening the vessel is not enough – Is Cerebrolysin the answer to improved longterm outcome after recanalization therapy?

LIVE Starts on November 19, 2024 at 13:00 - 14:00 CET
Register now

What can you expect from this webinar?

The ongoing CERECAP (CErebrolysinRECanalizationAndPerfusion) pilot-trial series aims to answer the important question: Can a cytoprotective agent added to recanalization therapy improve longterm outcome and if yes, do specific patient groups benefits more than others? The panel consists of renowned stroke experts aiming to answer this important question and speak about their own clinical experiences using Cerebrolysin as add-on therapy as part of gold standard treatment.

Duration: 60 minutes

Languages: Webinar will be held in English language incl. subtitles if requested. Furthermore Russian and Ukrainian simultaneous translation will be offered.